The Research Institute for Tropical Medicine (RITM), through its National Tuberculosis Reference Laboratory (NTRL) certified two (2) participants from their Training of Trainers on TB Smear Microscopy (SM-TOT) course for the successful completion of their preceptorship last September 26-30, 2022.
The two (2) TOT-trained participants from the Department of Health (DOH) Central Luzon Center for Health Development (CHD) – now licensed TB Smear Microscopy Trainers, add to the cadre of competent trainers who will handle the training of implementers in Central Luzon.
Both participants achieved a score of at least 90% for their overall training management in terms of the five assessment categories – administration and management, logistics, lecture sessions, demonstration exercises, and return demonstration exercises.
Their preceptorship activity, supervised by NTRL, was held in DOH Central Luzon CHD Training Center where they capacitated nine participants on the Basic Course on TB Smear Microscopy.
According to NTRL Learning and Development Section (LDS) OIC-Head Louis Andrew Olazo, the preceptorship activity is the last and integral part of the SM-TOT course. It enables a structured and supportive period of transition in applying the set of skills required to prepare, manage, and conduct TB Smear Microscopy training for implementers in various regions.
With the decentralization of TB Smear Microscopy trainings to the subnational level, each region has its own cadre of trainers. However, over the years, the pool of regional trainers gradually decrease. NTRL aims to address this challenge through the conduct of SM-TOT.
“SM-TOT is essential in increasing the pool of regional trainers allowed to conduct TB Smear Microscopy Trainings and is of paramount importance in capacitating laboratory staff in performing various TB laboratory tests,” said Olazo.
NTRL is the laboratory arm of the National Tuberculosis Program (NTP) in the country mandated to conduct operational research, clinical research, and laboratory research especially for new diagnostics in support of clinical research for new TB drugs and vaccines.
by Allenor Enciso, Communication and Engagement Office